Sarcomas

The PD-1/antiangiogenic combination yielded a 24% ORR and 28-month median PFS, surpassing prior monotherapy benchmarks in refractory chordoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.

R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies such as pimicotinib in TGCT enables a tumor biology–informed approach to care.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

An NDA seeking the approval of varegacestat for the treatment of adult patients with desmoid tumors has been submitted to the FDA.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.

R. Lor Randall, MD, FACS, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Cogent Biosciences has submitted an NDA for bezuclastinib for patients with GIST who received prior imatinib.

R. Lor Randall, MD, FACS, highlights primary objectives of, and key takeaways from, the BOOM consensus meeting on PJI management in orthopedic oncology.

However, a trend towards OS benefit was observed when treatment with cabozantinib was deferred until after disease progression vs administered upfront.

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

The FDA indications for tazemetostat in relapsed/refractory follicular lymphoma and epithelioid sarcoma are being voluntarily withdrawn.

R. Lor Randall, MD, FACS, discusses a report on factors predicting local recurrence in nonmetastatic Ewing sarcoma from the phase 3 AEWS1031 trial.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Joseph Dominic Femino, MD, discusses breakthroughs in limb salvage surgery, including innovative ways to reconstruct bone and joints after resection.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

Philippos Costa, MD, and Hari Deshpande, MD, discuss chondrosarcoma staging, diagnosis, surgery, and future research avenues in this clinician-focused FAQ.

OS Therapies began a rolling submission of a BLA for OST-HER2 in fully resected pulmonary metastatic osteosarcoma.

The clinical benefit and disease control rates were both 100% with lurbinectedin plus ipilimumab/nivolumab in patients with advanced soft tissue sarcoma.

Treatment with first-line metronomic cyclophosphamide did not significantly improve TTF, PFS, or OS vs doxorubicin in advanced soft tissue sarcoma.